Peer-reviewed veterinary case report
Photodynamic therapy with glucose-chlorin e6 for dog tumors
By Osaki, Tomohiro et al.·Published in Veterinary medicine and science·2023·Faculty of Agriculture, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Vascular-targeted photodynamic therapy with glucose-conjugated chlorin e6 for dogs with spontaneously occurring tumours.
- Species:
- dog
Plain-English summary
A group of five dogs with different types of cancer, including malignant melanoma and squamous cell carcinoma, received a new treatment called vascular-targeted photodynamic therapy (VTP) using a special drug called glucose-conjugated chlorin e6 (G-Ce6). After being injected with G-Ce6, the dogs were treated with a laser, which resulted in a decrease in tumor size and complete remission in three of the dogs. Some dogs experienced mild side effects like swelling around the treatment area, but these resolved on their own. Overall, VTP with G-Ce6 showed promising results in treating these tumors in dogs.
People also search for: dog cancer treatment · photodynamic therapy for dogs · glucose-conjugated chlorin e6 · dog tumor remission · malignant melanoma in dogs
Abstract
BACKGROUND: Photodynamic therapy (PDT) using photosensitisers is a minimally invasive treatment for malignant tumours. However, ideal photosensitisers are not yet established. Recently, we developed a new photosensitiser, glucose-conjugated chlorin e6 (G-Ce6). OBJECTIVES: To evaluate the clinical efficacy of vascular-targeted PDT (VTP), a type of PDT utilising a short drug-light interval, using G-Ce6 to treat spontaneously occurring tumours in dogs. METHODS: Five dogs with spontaneously occurring tumours (malignant melanoma: three; haemangiopericytoma: two; and squamous cell carcinoma: one) were subjected to VTP. These dogs were intravenously injected with G-Ce6 at doses of 1-3 mg/kg 5 min before laser irradiation. Tumours were superficially or interstitially irradiated using a 677-nm diode laser. RESULTS: Repeated VTP decreased tumour size, yielding complete remission in three dogs. Complications such as oedema surrounding normal tissues and fistulae were observed, and the oedema was self-limiting. The fistula was cured by debriding the necrotic tissues formed after VTP. CONCLUSIONS: Our findings demonstrate that VTP using G-Ce6 had antitumour effects in dogs with spontaneously occurring tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37715623/